At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology. The post At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor appeared first on MedCity News.
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology.
The post At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor appeared first on MedCity News.
